leisure time -WSS

leisure time

author：comprehensive 2025-10-02 00:28:10 - browse：7

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Research misconduct: Proposed new rules face resistance

knowledge

hotspot

WSS

The tragedy of Johnson & Johnson’s Covid vaccine

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

The biotech scorecard for Q1: 17 stock

Chronically ill young patients struggle to find fertility info

My yearlong odyssey to get my son’s ADHD medication covered

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

focus

leisure time

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Elizabeth Holmes banned from government health programs

Peter Hotez and the public health issue of online harassment

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

J&J to buy cancer drug developer Ambrx Biopharma

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why psychiatrists like me stop taking insurance

Novavax promises a turnaround & Lilly roils the obesity market

3 trends to watch in health tech's hiring outlook for 2024

hotspot

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Morgan Health, with ambitious aims, wants you to know it’s still here

White House finalizes ITC's import ban of latest Apple Watches

U.K. sequencing study surfaces new findings about tumor DNA

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Dewpoint Therapeutics lays off staff after losing partnerships

knowledge

leisure time

hotspot

leisure time